We previously showed that the 44-kDa
serine/threonine kinase Pim-1 (Pim-1L) can protect
prostate cancer cells from apoptosis induced by chemotherapeutic drugs (Xie, Y., Xu, K., Dai, B., Guo, Z., Jiang, T., Chen, H., and Qiu, Y. (2006) Oncogene 25, 70-78). To further explore the mechanisms of Pim-1L-mediated resistance to chemotherapeutic drugs in
prostate cancer cells, we employed a yeast two-hybrid screening to identify cellular
proteins that were associated with Pim-1L, and we found the
ABC transporter BCRP/ABCG2 as one of the potential interacting partners of Pim-1L. We also showed that the expression level of Pim-1L and BCRP was up-regulated in
mitoxantrone and
docetaxel-resistant
prostate cancer cell lines. Pim-1L was co-localized with BCRP on the plasma membrane and induced phosphorylation of BCRP at
threonine 362. Knocking-down Pim-1L expression in the
drug-resistant
prostate cancer cells abolished multimer formation of endogenous BCRP and resensitized the resistant cells to chemotherapeutic drugs suggesting that BCRP phosphorylation induced by Pim-1L was essential for its functionality. This is further corroborated by our finding that the plasma membrane localization and
drug-resistant activity of BCRP were compromised by T362A mutation. Our data suggest that Pim-1L may protect
prostate cancer cells from apoptosis, at least in part, through regulation of transmembrane
drug efflux pump. These findings may provide a potential therapeutic approach by disrupting Pim-1 signaling to reverse BCRP-mediated multidrug resistance.